These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7082424)

  • 1. A drug sensitivity test strategy for atypical mycobacteria.
    Hejný J
    Tubercle; 1982 Mar; 63(1):63-9. PubMed ID: 7082424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility to antibiotics and sulfonamides of atypical mycobacteria isolated in South America.
    de Kantor IN; Barrera L; di Lonardo M
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Oct; 260(2):247-53. PubMed ID: 4082825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mycobacterial bases of the therapy of mycobacterioses].
    Hejný J
    Z Erkr Atmungsorgane; 1982; 158(1-2):163-7. PubMed ID: 7072265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods for determining the antimicrobial susceptibility of mycobacteria.
    Alcaide F; Esteban J; González-Martin J; Palacios JJ
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):529-535. PubMed ID: 27236235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo susceptibility of atypical mycobacteria to various drugs.
    Kuze F; Kurasawa T; Bando K; Lee Y; Maekawa N
    Rev Infect Dis; 1981; 3(5):885-97. PubMed ID: 7339820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of Mycobacterium fortuitum to non-antituberculous antibacterial agents.
    Casal MJ; Rodriguez FC
    Ann Microbiol (Paris); 1983; 134A(1):73-8. PubMed ID: 6847037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid mycobacteria drug susceptibility testing using Gel Microdrop (GMD) Growth Assay and flow cytometry.
    Akselband Y; Cabral C; Shapiro DS; McGrath P
    J Microbiol Methods; 2005 Aug; 62(2):181-97. PubMed ID: 16009276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of Mycobacterium gordonae from Mycobacterium scrofulaceum and Mycobacterium szulgai by susceptibility to enoxacin (antimycobacterial activity of enoxacin).
    Tsukamura M
    Microbiol Immunol; 1986; 30(9):931-3. PubMed ID: 3467156
    [No Abstract]   [Full Text] [Related]  

  • 9. Isolation-drug resistance profile and molecular characterization of indigenous typical and atypical mycobacteria.
    Khanum T; Rasool SA; Ajaz M; Khan AI
    Pak J Pharm Sci; 2011 Oct; 24(4):527-32. PubMed ID: 21959816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Distribution and drug resistance of nontuberculous
    Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Mar; 40(3):210-214. PubMed ID: 28297817
    [No Abstract]   [Full Text] [Related]  

  • 11. In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs.
    Marinis E; Legakis NJ
    J Antimicrob Chemother; 1985 Oct; 16(4):527-30. PubMed ID: 2933382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basis for lack of drug susceptibility of atypical mycobacteria.
    David HL
    Rev Infect Dis; 1981; 3(5):878-84. PubMed ID: 7339819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activity of quinolones and macrolides against mycobacteria.
    Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
    J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of the new macrolide A-56268 against mycobacteria.
    Berlin OG; Young LS; Floyd-Reising SA; Bruckner DA
    Eur J Clin Microbiol; 1987 Aug; 6(4):486-7. PubMed ID: 2959472
    [No Abstract]   [Full Text] [Related]  

  • 15. New antibiotics, resorcinomycins A and B: antibacterial activity of resorcinomycin A against mycobacteria in vitro.
    Masaki S; Konishi T; Tsuji N; Shoji J
    J Antibiot (Tokyo); 1989 Mar; 42(3):463-6. PubMed ID: 2708139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in the bacteriology of tuberculosis (including drug resistance and atypical Mycobacteria).
    Laidlaw M
    Scott Med J; 1978 Apr; 23(2):181. PubMed ID: 644301
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibacterial activities of dendritic amphiphiles against nontuberculous mycobacteria.
    Falkinham JO; Macri RV; Maisuria BB; Actis ML; Sugandhi EW; Williams AA; Snyder AV; Jackson FR; Poppe MA; Chen L; Ganesh K; Gandour RD
    Tuberculosis (Edinb); 2012 Mar; 92(2):173-81. PubMed ID: 22209468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of antibiotic resistance in Mycobacterium intracellulare.
    Mizuguchi Y; Udou T; Yamada T
    Microbiol Immunol; 1983; 27(5):425-31. PubMed ID: 6312275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.
    Wallace RJ; Swenson JM; Silcox VA; Bullen MG
    J Infect Dis; 1985 Sep; 152(3):500-14. PubMed ID: 3875667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
    Vacher S; Pellegrin JL; Leblanc F; Fourche J; Maugein J
    J Antimicrob Chemother; 1999 Nov; 44(5):647-52. PubMed ID: 10552981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.